Goldman Sachs Resumes Coverage on Glimcher Realty Trust (GRT) at Neutral; Turnaround Strides, But High Leverage
Get Alerts GRT Hot Sheet
Price: $14.06 --0%
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs resumes coverage on Glimcher Realty Trust (NYSE: GRT) with a Neutral. PT $11.00.
Analyst, Andrew Rosivach, said, "GRT should show material 2013 earnings growth (16% versus our sector at 8%) as it comps against below-normal 2012 earnings (the company had $0.04 per share of earnings drag related to the investment of proceeds from its 1Q 2012 equity offering)...Potential capital recycling dilution related to portfolio improvement places our 2012-17 FFO growth estimate (34%) slightly below the sector average (38%)."
For an analyst ratings summary and ratings history on Glimcher Realty Trust click here. For more ratings news on Glimcher Realty Trust click here.
Shares of Glimcher Realty Trust closed at $10.41 yesterday.
Analyst, Andrew Rosivach, said, "GRT should show material 2013 earnings growth (16% versus our sector at 8%) as it comps against below-normal 2012 earnings (the company had $0.04 per share of earnings drag related to the investment of proceeds from its 1Q 2012 equity offering)...Potential capital recycling dilution related to portfolio improvement places our 2012-17 FFO growth estimate (34%) slightly below the sector average (38%)."
For an analyst ratings summary and ratings history on Glimcher Realty Trust click here. For more ratings news on Glimcher Realty Trust click here.
Shares of Glimcher Realty Trust closed at $10.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share